daprodustat daprodustat daprodustat, sold under the brand name duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease. it is a hypoxia-inducible factor prolyl hydroxylase inhibitor. it is taken by mouth. daprodustatclinical datatrade namesduvroq, jesduvroqother namesgsk1278863license data us dailymed: daprodustat routes ofadministrationby mouthdrug classhypoxia-inducible factor prolyl hydroxylase inhibitoratc codeb03xa07 (who) legal statuslegal status us: ℞-only in general: ℞ (prescription only) identifiers iupac name 2-acetic acid cas number960539-70-2pubchem cid91617630drugbankdb11682chemspider33427356uniijvr38zm64bkeggd10874chemblchembl3544988echa infocard100.219.426 chemical and physical dataformulac19h27n3o6molar mass393.440 g·mol−13d model (jsmol)interactive image smiles c3ccccc3n(c(=o)c1c(=o)ncc(=o)o)c(=o)n(c1o)c2ccccc2 inchi inchi=1s/c19h27n3o6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,26h,1-11h2,(h,20,25)(h,23,24)key:nvtkjbxobfrplq-uhfffaoysa-n the most common side effects include high blood pressure, thrombotic vascular events, abdominal pain, dizziness and allergic reactions. daprodustat was approved for medical use in japan in june 2020, and in the united states in february 2023. it is the first oral treatment for anemia caused by chronic kidney disease for adults. medical uses daprodustat is indicated for the treatment of anemia due to chronic kidney disease. history daprodustat increases erythropoietin levels. the effectiveness of daprodustat was established in a randomized study of 2,964 adult participants receiving dialysis. in this study, participants received either oral daprodustat or injected recombinant human erythropoietin (a standard of care treatment for people with anemia due to chronic kidney disease). daprodustat raised and maintained the hemoglobin (the protein in red blood cells that carries oxygen and is a common measure of anemia) within the target range of 10-11 grams/deciliter, similar to that of the recombinant human erythropoietin. the us food and drug administration (fda) granted the approval of jesduvroq to glaxosmithkline llc. society and culture due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs. research daprodustat is in phase iii clinical trials for the treatment of anemia caused by chronic kidney disease.